论文部分内容阅读
随着肿瘤发病机理的深入研究及众多抗癌药物的出现,肿瘤的临床化疗越来越重要。少数肿瘤单用药物疗法即可达到满意效果。多数临床化疗遇到的问题除药物特异性不高及毒副反应常见(即治疗指数偏低)之外,更为重要的问题是肿瘤细胞的抗药性(drug resistance)。常遇到这样的情况:肿瘤在治疗初期对某种药物很敏感,但经过几个疗程后,其敏感性逐渐下降,不得不改用他药或联合化疗。有时甚至对结构与功能不相关的多种药物产生抗药性,即所谓多向交叉抗药。关于抗药性出现
With the in-depth study of the pathogenesis of tumors and the emergence of numerous anticancer drugs, the clinical chemotherapy of tumors is increasingly important. A small number of tumors can achieve satisfactory results with drug therapy alone. The problems encountered by most clinical chemotherapy, besides the low specificity of the drug and the common toxicity (ie, low therapeutic index), the more important issue is the drug resistance of tumor cells. Often encountered in this situation: the tumor is very sensitive to a drug in the early treatment, but after a few courses, the sensitivity gradually decreased, had to switch to his drug or combined chemotherapy. Sometimes it even develops resistance to multiple drugs that are not related to structure and function, so-called multi-directional cross-resistance drugs. About emergence of drug resistance